AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04927780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV
Study NCT06240806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manuka Honey
Description: Manuka honey will be topically applied to the oral mucosa as oral rinse based on the Biswal et al., 2003 administration protocol.
Study NCT06240806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline mouthwash
Description: Saline mouthwash will be used 3 times per day for one month
Study NCT04763850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decline Walking with real-time Feedback
Description: Participants are walking decline with self-paced speed on an instrumented treadmill with virtual reality projection under three conditions: without instruction, with instruction for an internal focus of attention and with real-time feedback of their frontal knee alignment
Study NCT05960500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant
Description: All on six versus parallel implant distribution
Study NCT06196762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XKH002 Injection
Description: 240 mg/4 mL/vial（60 mg/mL）
Study NCT05974969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-264
Description: a single intravenous infusion of BCD-264
Study NCT05974969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darzalex
Description: a single intravenous infusion of Darzalex
Study NCT06435234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: risky sexual behavior intervention
Description: Intervening in risky sexual behaviors among college students
Study NCT05635994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AID strategy
Description: AID strategy encompasses a hierarchical algorithm intended to investigate both obstructive and non-obstructive causes of myocardial ischaemia. AID strategy starts with an ICA. Angiographically severe-grade stenosis (≥70%) can be safely considered flow-limiting without further physiological assessment. Conversely, by means of a pressure guidewire, intermediate-grade stenosis should be evaluated with FFR and/or NHPR in order to determine if they are physiologically significant. Those patients with non-obstructive CAD or normal epicardial coronary arteries should undergo functional coronary tests to investigate the presence of microcirculatory and vasomotor coronary disorders, which would account for non-obstructive causes of ischaemia.
Study NCT05678621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole (co-trimoxazole)
Description: Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
Study NCT05678621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanic acid and ciprofloxacin
Description: clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
Study NCT05678621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulins
Description: Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
Study NCT04809779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: The PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments.
Study NCT04859855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restrictive transfusional strategy
Description: Transfusion of Red Blood Concentrates (RBCs) if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
Study NCT04859855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liberal transfusional strategy
Description: Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL
Study NCT05044403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal support with haemoperfusion
Description: Use of extracorporeal support with haemoperfusion
Study NCT05044403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment
Study NCT06502041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MARPE with MOP
Description: mini-screw assisted rapid palatal expansion with micro-osteoperforation
Study NCT06502041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MARPE without MOP
Description: mini-screw assisted rapid palatal expansion without micro-osteoperforation
Study NCT05926882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
Study NCT06442683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TTE simulation-based medical training
Description: half-day simulation-based neonatal echocardiography training.
Study NCT05736237 — intervention group
Intervention type: GENETIC
Intervention: Whole exome sequencing
Description: With Next Generation Sequenzing
Study NCT04694300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: 440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days.
Study NCT04694300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
Study NCT04694300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 50 mg by mouth every 6 hours as needed for pain
Study NCT05041335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wet heparinzed suction
Description: Needle flushed with 5000 Units in 10mL of heparin
Study NCT05041335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microsieve
Description: A microsieve used for tissue preparation
Study NCT05041335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No heparin flush
Description: The needle not prepped
Study NCT05041335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No heparin flush
Description: The needle not prepped
Study NCT05041335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No microsieve
Description: The tissue is placed into formalin
Study NCT05041335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No microsieve
Description: The tissue is placed into formalin
Study NCT06454357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B007
Description: B007：high dose/low dose: Subcutaneous injection was administered on days 1 and 15
Study NCT05567328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Research FibroScan (FS)
Description: Exams will be performed with the M or XL probe as per FS recommendations. Same probe must be used for all exams Exploratory exam after patient 151 are performed with adapted view of Research FS~Patients 1 to 90 \& 151 to 190 Exam1 Exploratory exam with the Research FS Exam2 Reference exam with the CE-marked FS~Patients 91 to 130 \& 191 to 230 Exams1\&2 Two consecutive Exploratory exams with the Research FS Exams3\&4 Two consecutive Reference exams with the CE-marked FS~Patients 131 to 150 Exams1\&2 Two consecutive Exploratory exams with automatic function of the Research FS Exam3 Reference exam with the CE-marked FS~Patients 231 to 270 Exams1 (novice operator) Exploratory exam with the Research FS Exams2 (novice operator) Reference exam with the CE-marked FS Exams3 (experienced/expert operator) Exploratory exam with the Research FS Exams4 (experienced/expert operator) Reference exam with the CE-marked FS
Study NCT05958017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reSET
Description: Participants in this group will use a mobile application that delivers treatment for substance use disorder. 31 required and 30 optional modules. Among many topics covered in the modules, some are substance use management, communication, emotion management, relationship skills, HIV/Sexually Transmitted Infections and triggers for risky sex. In the reSET app you will get the chance to earn rewards for two activities: (1) completing a module and (2) providing a negative urine drug screen in exchange for a motivational or monetary prize. You will have 12 weeks to complete as many modules as you like, about 4 modules per week. Each module takes approximately 10-15 min. Every 3-4 days you will meet with the same study team member to provide a urine drug screen from a place comfortable for you (e.g. home) which will be observed and read via Zoom.
Study NCT05958017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Participants in this group will receive assistance connecting to an in person community-based outpatient treatment program.
Study NCT05566379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness - Mindful Awareness Practices ( MAPs)
Description: All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center at UCLA. Participants will learn Mindful concepts and a variety of Mindfulness practices. This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. MAPs classes meets weekly for two hours per week for six weeks. Participants are encouraged to complete some daily meditation practice starting at five minutes a day and working up to 20 minutes daily by the end of the course.
Study NCT04927780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV
Study NCT04927780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Open or minimally-invasive pancreatectomy.
Study NCT05031481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venus 20 + 0,064
Description: Venus vaginal cream 20 + 0,064, single-dose.
Study NCT05031481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venus 20 + 1
Description: Venus vaginal cream 20 + 1, single-dose.
Study NCT05031481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venus 20 + 4
Description: Venus vaginal cream 20 + 4, single-dose.
Study NCT05031481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Butoconazole nitrate
Description: Butoconazole nitrate vaginal cream, 100 mg single-dose.
Study NCT04839224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbogen
Description: Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.
Study NCT04839224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine
Description: Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
Study NCT04756141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: A CGM will be placed on patients with diabetes mellitus and COVID-19 infection and interstitial glucose will be monitored continuously while the patients are in the hospital.
Study NCT06404697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost irradiation
Description: High-risk patients will undergo boost irradiation to the SCV with a cumulative dose of ≥60 Gy.
Study NCT04758871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 MG Oral Tablet
Description: 10 mg three times daily
Study NCT05776225 — intervention group
Intervention type: PROCEDURE
Intervention: Right heart catheterization (RHC)
Description: RHC to evaluate pulmonary hemodynamics
Study NCT06046001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirWaze
Description: AirWaze - easy and advanced tools for CBCT guided lung interventions
Study NCT06457503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.
Study NCT06457503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
Study NCT06457503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.
Study NCT04758871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone
Description: 2x 200 mg vaginal tablets two times daily
Study NCT05593406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Group
Description: Whole body vibration for 15 minutes in squat and lunge position.
Study NCT05593406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: NDT treatment 2 sessions per week
Study NCT04927780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Open or minimally-invasive pancreatectomy.
Study NCT04694300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: 50 mg by mouth every 6 hours as needed for pain
Study NCT05446090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry including peak flow
Description: Spirometry including peak flow to assess the degree of airway obstruction. Spirometry will be conducted according to a study SOP. The Global Lung Function (GLI) 2012 equations will be used. Reversibility testing will not be routinely performed. Thus, asthma medications will not normally be withheld for study visits and patients should take their inhalers as usual. The same type of device will be used at each visit.
Study NCT05446090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional Exhaled Nitric Oxide (FeNO)
Description: Fractional Exhaled Nitric Oxide (FeNO) to assess the degree of airway inflammation. FeNO will be measured using a standard device (NIOXX Vero®) in accordance with the manufacturer's guidelines. The same type of device will be used at each visit. FeNO should be performed prior to any other respiratory assessment if possible.
Study NCT05446090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Forced Oscillation Technique (FOT)
Description: FOT is a non-invasive method that evaluates resistance and reactance in the respiratory system during tidal breathing. It should be performed after FeNO, but prior to Spirometry and will be conducted according to a study SOP.
Study NCT05446090 — intervention group
Intervention type: PROCEDURE
Intervention: Sputum Induction
Description: Sputum Induction for the assessment of airway inflammation and microbiology. Sputum induction will be performed according to an SOP, which includes measures to protect the safety of participants. These consist of pre-treatment with Salbutamol, a short acting bronchodilator, stipulated levels of lung function in order to perform the test and stopping criteria. If the participant is unable to undergo the procedure, due to safety reasons, they will be asked to produce a spontaneous sputum sample. Sputum samples will be collected for a differential cell count, bacterial culture and sensitivity and storage for future research. Procedures for sampling and processing will be detailed in a study SOP.
Study NCT05446090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bloods
Description: Blood will be collected for laboratory analysis, including Vitamin D, Haematology, WCC differential, C-Reactive protein.
Study NCT05446090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal lavage
Description: Nasal lavage samples will be taken at the baseline (attack) visit. Samples will be obtained by injecting 5ml of sterile normal saline into the participant's nostrils via a nasal adaptor and then immediately aspirated. These will be placed in a sterile container and transported to the laboratory for viral identification. This procedure will be detailed in a study SOP.
Study NCT05376735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purrble intervention
Description: The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing.~The Purrble is introduced to the student as an anxious creature that may need kind attention from humans. When picked up, the Purrble emits a frantic heartbeat that slows down if the child uses calm stroking movements. If it's soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to students in emotional moments when they would attempt to practice emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in students' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2.
Study NCT06457503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
Study NCT05446090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Throat swab
Description: A throat swab will be taken at the baseline (attack) visit for viral identification.
Study NCT05376735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Intervention
Description: The SSI has been co-produced with university students and clinical experts, combining the theories of ER with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~* Initial guided reflection exercise (helping understand one's experience with Purrble in the 1st week).~* Short interactive psychoeducation, introducing the concept of window of tolerance, the Process Model of Emotions (Gross2015), and specific ways in which Purrble can help students down-regulate emotions within the context of the process model.~* Action plan to identify: moments when Purrble could be useful, what ER strategies they would like to use in those moments, what obstacles they may encounter, and how to overcome them.~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes.
Study NCT05446090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal Brush.
Description: Nasal brushings samples may be taken at baseline (attack) and at second visits for RNA and DNA extraction. This will be optional and specific consent from participants will be sought. Procedures for sampling and processing will be detailed in a study SOP.
Study NCT05446090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal absorption
Description: Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.
Study NCT05446090 — intervention group
Intervention type: OTHER
Intervention: Medical History, Demographic, and Concomitant Medications
Description: Medical history will include clinically significant diseases and prior surgeries and smoking history. A specific respiratory history will also be recorded. Demographic data will include age, sex and self- reported race/ethnicity. Medication use will also be collected.
Study NCT05446090 — intervention group
Intervention type: OTHER
Intervention: Sino-nasal Outcome Test
Description: The incidence of upper airway symptoms will be assessed using Sino-nasal Outcome Test (SNOT).
Study NCT05446090 — intervention group
Intervention type: OTHER
Intervention: Gastroesophageal Reflux Disease Questionnaire
Description: The incidence of Gastroesophageal Reflux Disease will be assessed using GERDQ questionnaire.
Study NCT05446090 — intervention group
Intervention type: OTHER
Intervention: Pittsburgh Vocal Cord Dysfunction Index
Description: The incidence of vocal cord dysfunction will be assessed using Pittsburgh Vocal Cord Dysfunction (VCD) Index
Study NCT05446090 — intervention group
Intervention type: OTHER
Intervention: Nijmegen Questionnaire.
Description: The incidence of dysfunctional breathing will be assessed using Nijmegen dysfunctional questionnaire.
Study NCT05446090 — intervention group
Intervention type: OTHER
Intervention: Hospital Anxiety and Depression Scale
Description: The incidence of anxiety and depression will be assessed using Hospital Anxiety and Depression Scale (HADS).
Study NCT05446090 — intervention group
Intervention type: OTHER
Intervention: Compliance and adherence
Description: In order to assess adherence as a factor in exacerbations, a participant's beliefs and attitudes towards medicines will be explored using the Medicines Adherence Report Scale (MARS) questionnaire. Non-intentional non-compliance with usual treatment will be assessed by checking inhaler technique; poor inhaler technique will be reported to the participant's clinical team. Also, GP records will be reviewed for information on medications prescribed in the last 12 months.
Study NCT05446090 — intervention group
Intervention type: OTHER
Intervention: Acute Asthma Quality of Life Questionnaire
Description: The impact of acute asthma on quality of life will be assessed using Acute Asthma Quality of Life Questionnaire at baseline and follow up.
Study NCT06081725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Playful interactions in an online format
Description: The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game. The intervention will be conducted by zoom